NovoCure (STU:038) Net Change in Cash : €248.7 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is NovoCure Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

NovoCure's Net Change in Cash for the three months ended in Mar. 2024 was €197.6 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was €248.7 Mil.

NovoCure Net Change in Cash Historical Data

The historical data trend for NovoCure's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Net Change in Cash Chart

NovoCure Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

32.99

54.88

-32.36

-88.52

116.21

NovoCure Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															66.13	-26.90	-0.92	78.91	197.62

NovoCure Net Change in Cash Calculation

NovoCure's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-67.249	+	168.864	+	14.477	+	0.12
	=	116.2

NovoCure's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -29.048 + 226.519 + 0.196 + -0.052

= 197.6

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €248.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure Net Change in Cash Related Terms
Thank you for viewing the detailed overview of NovoCure's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure (STU:038) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (STU:038) » Definitions » Net Change in Cash

Comparable Companies

SSII PRCT ATEC INMD TMDX UFPT TNDM AHCO PACB AVNS ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA

Traded in Other Exchanges

NVCR:USA

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (STU:038) Headlines

No Headlines